Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 2 |
2020 | 4 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells.
Front Oncol. 2022 Jun 20;12:925718. doi: 10.3389/fonc.2022.925718. eCollection 2022.
Front Oncol. 2022.
PMID: 35795040
Free PMC article.
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer.
Miller AL, Garcia PL, Fehling SC, Gamblin TL, Vance RB, Council LN, Chen D, Yang ES, van Waardenburg RCAM, Yoon KJ.
Miller AL, et al.
Cancers (Basel). 2021 Jul 11;13(14):3470. doi: 10.3390/cancers13143470.
Cancers (Basel). 2021.
PMID: 34298684
Free PMC article.
Item in Clipboard
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma.
Miller AL, Garcia PL, Gamblin TL, Vance RB, Yoon KJ.
Miller AL, et al.
Cancer Drug Resist. 2020;3(3):572-585. doi: 10.20517/cdr.2020.35. Epub 2020 Aug 7.
Cancer Drug Resist. 2020.
PMID: 33073205
Free PMC article.
Item in Clipboard
Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models.
Garcia PL, Miller AL, Yoon KJ.
Garcia PL, et al.
Cancers (Basel). 2020 May 22;12(5):1327. doi: 10.3390/cancers12051327.
Cancers (Basel). 2020.
PMID: 32456018
Free PMC article.
Review.
Item in Clipboard
Developing effective combination therapy for pancreatic cancer: An overview.
Miller AL, Garcia PL, Yoon KJ.
Miller AL, et al.
Pharmacol Res. 2020 May;155:104740. doi: 10.1016/j.phrs.2020.104740. Epub 2020 Mar 2.
Pharmacol Res. 2020.
PMID: 32135247
Free PMC article.
Review.
Item in Clipboard
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.
Fehling SC, Miller AL, Garcia PL, Vance RB, Yoon KJ.
Fehling SC, et al.
Cancer Lett. 2020 Jan 1;468:48-58. doi: 10.1016/j.canlet.2019.10.011. Epub 2019 Oct 9.
Cancer Lett. 2020.
PMID: 31605774
Free PMC article.
Item in Clipboard
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Miller AL, Fehling SC, Garcia PL, Gamblin TL, Council LN, van Waardenburg RCAM, Yang ES, Bradner JE, Yoon KJ.
Miller AL, et al.
EBioMedicine. 2019 Jun;44:419-430. doi: 10.1016/j.ebiom.2019.05.035. Epub 2019 May 22.
EBioMedicine. 2019.
PMID: 31126889
Free PMC article.
Item in Clipboard
Cite
Cite